

Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment

Joseph P. McEvoy, M.D.

Jeffrey A. Lieberman, M.D.

T. Scott Stroup, M.D., M.P.H.

Sonia M. Davis, Dr.P.H.

Herbert Y. Meltzer, M.D.

Robert A. Rosenheck, M.D.

Marvin S. Swartz, M.D.

Diana O. Perkins, M.D., M.P.H.

Richard S.E. Keefe, Ph.D.

Clarence E. Davis, Ph.D.

Joanne Severe, M.S.

John K. Hsiao, M.D.

for the CATIE Investigators

Objective: When a schizophrenia patient has an inadequate response to treatment with an antipsychotic drug, it is unclear what other antipsychotic to switch to and when to use clozapine. In this study, the authors compared switching to clozapine with switching to another atypical antipsychotic in patients who had discontinued treatment with a newer atypical antipsychotic in the context of the Clinical Antipsychotic Trials for Interventions Effectiveness (CATIE) investigation.

Method: Ninety-nine patients who discontinued treatment with olanzapine, quetiapine, risperidone, or ziprasidone in phase 1 or 1B of the trials, primarily because of inadequate efficacy, were randomly assigned to open-label treatment with clozapine (N=49) or blinded treatment with another newer atypical antipsychotic not previously received in the trial (olanzapine [N=19], quetiapine [N=15], or risperidone [N=16]).

Results: Time until treatment discontinuation for any reason was significantly longer for clozapine (median=10.5 months) than for quetiapine (median=3.3), risperidone (median=2.8), and olanzapine (median=2.7). Time to discontinuation because of inadequate therapeutic effect was significantly longer for clozapine than for olanzapine, quetiapine, and risperidone. At 3-month assessments, Positive and Negative Syndrome Scale total scores had decreased more in patients treated with clozapine than in patients treated with quetiapine or risperidone but not olanzapine. One patient treated with clozapine developed agranulocytosis, and another developed eosinophilia; both required treatment discontinuation.

Conclusions: For these patients with schizophrenia who prospectively failed to improve with an atypical antipsychotic, clozapine was more effective than switching to another newer atypical antipsychotic. Safety monitoring is necessary to detect and manage clozapine's serious side effects.

(*Am J Psychiatry* 2006; 163:600–610)

Clozapine is generally considered to be the most effective antipsychotic drug. Studies of patients who had inadequate therapeutic response to conventional neuroleptic drugs have incontrovertibly demonstrated that clozapine is more effective than treatment with another conventional neuroleptic (1–6). Additional studies have suggested that clozapine may be superior to other atypical antipsychotics in controlling symptoms that are not responsive to conventional drugs in patients with chronic schizophrenia (7, 8). Few studies, however, have examined the effectiveness of clozapine in patients who have not responded to an atypical antipsychotic drug. Moreover, because of clozapine's burden of serious side effects, it is not known whether multiple trials involving some or all of the newer atypical antipsychotics should be undertaken before treating a patient with clozapine (9).

Phase 2 of the Clinical Antipsychotic Trials for Interventions Effectiveness (CATIE) investigation was designed to

address this question. In particular, patients who discontinued treatment with a newer atypical antipsychotic in phase 1 or 1B of the CATIE investigation because of suboptimal control of psychopathology were invited to undergo another random assignment to clozapine or to another atypical antipsychotic (olanzapine, quetiapine, or risperidone) other than what they had received in phase 1. However, such patients also had the option to select another phase 2 trial (Stroup et al., this issue), and patients who discontinued treatment in phase 1 or 1B for other reasons could also select “the clozapine trial.”

Method

Study Setting and Design

The National Institute of Mental Health initiated the CATIE investigation to determine the comparative effectiveness of antipsychotic drugs. The rationale, design, and methods of the trials

TABLE 1. Baseline Demographic and Clinical Characteristics of Patients Randomly Assigned to Clozapine or Another Atypical Antipsychotic

Characteristic at Phase 2 Baseline	Clozapine (N=49)		Olanzapine (N=19)		Quetiapine (N=15)		Risperidone (N=16)		Total (N=99)	
	N	%	N	%	N	%	N	%	N	%
Male gender	40	82	18	95	12	80	10	63	80	81
Race										
White	32	65	11	58	9	60	11	69	63	64
Black/African American	14	29	8	42	6	40	5	31	33	33
All other racial groups ^a	3	6	0	0	0	0	0	0	3	3
Spanish/Hispanic/Latino ethnicity	8	16	1	5	0	0	5	31	14	14
Married ^b	2	4	2	11	4	27	1	6	9	9
Unemployed ^c	42	88	15	79	14	93	13	81	84	86
Structured Clinical Interview for DSM-IV diagnosis present in the past 5 years										
Depression	12	24	5	26	9	60	7	44	33	33
Alcohol dependence or alcohol abuse	13	27	5	26	2	13	5	31	25	25
Drug dependence or drug abuse	9	18	4	21	6	40	5	31	24	24
Antipsychotic medication received in prior phase (1/1A or 1B)										
Olanzapine	10	20	—	—	5	33	4	25	19	19
Quetiapine	18	37	10	53	—	—	9	56	37	37
Risperidone	16	33	6	32	8	53	—	—	30	30
Ziprasidone	5	10	3	16	2	13	3	19	13	13
Reason for discontinuation from prior phase (1/1A or 1B)										
Inadequate therapeutic effect	44	90	16	84	12	80	13	81	85	86
Unacceptable side effects	3	6	0	0	1	7	1	6	5	5
Patient decision	2	4	3	16	2	13	1	6	8	8
Administrative decision	0	0	0	0	0	0	1	6	1	1
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Age (years)	39.4	9.9	44.3	10.5	37.1	11.8	37.7	9.3	39.7	10.4
Education (years) ^c	12.6	1.8	13.3	2.7	12.3	1.4	12.3	1.8	12.6	2.0
Psychiatric history										
Age of first treatment for any behavioral or emotional problem (years) ^d	21.2	7.5	26.5	9.5	22.5	9.2	24.1	8.8	22.9	8.5
Years since first antipsychotic medication received ^e	13.8	8.7	14.5	8.9	10.8	9.0	11.1	10.8	13.0	9.1
Psychopathology										
Positive and Negative Syndrome Scale total score (range=30–210)	90.3	21.3	83.1	19.1	91.1	22.2	81.4	14.6	87.6	20.2
Clinician-rated Clinical Global Impression severity score (range=1–7)	4.7	0.9	4.3	1.2	4.9	0.7	4.3	0.7	4.6	0.9
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Time until treatment discontinuation for any reason in phase 1 (months) ^f	4.8	4.2	3.8	2.9	4.1	3.4	5.1	3.0	4.5	3.7

^a Other racial groups include Asian (2%) and two or more races (1%).

^b Previously married and never married categories were combined such that the p value for the test of marital status results from a comparison between married and not married.

^c Baseline employment status and years of education in phase 1 were missing for one patient in the clozapine arm; hence, the corresponding column percentage is based on 48 patients.

^d Group size was clozapine (N=46), olanzapine (N=17), quetiapine (N=15), and risperidone (N=16).

^e Group size was clozapine (N=47), olanzapine (N=17), quetiapine (N=15), and risperidone (N=15).

^f Median values for groups in the last row were the following: clozapine (3.0), olanzapine (2.8), quetiapine (3.1), risperidone (N=4.0), total (3.1).

have been described in detail (10, 11). The trials were conducted between January 2001 and December 2004 at 57 clinical sites in the United States. The patients were initially randomly assigned to treatment with olanzapine, quetiapine, risperidone, ziprasidone, or perphenazine in the phase 1 trial. Patients with tardive dyskinesia at baseline were excluded from random assignment to perphenazine. Patients who discontinued treatment with perphenazine in phase 1 could subsequently enter a trial involving

random assignment to olanzapine, quetiapine, or risperidone (phase 1B) before entering phase 2. Any patient who discontinued treatment with olanzapine, quetiapine, risperidone, or ziprasidone in phases 1 or 1B was eligible to participate in one of the phase 2 trials. If the assigned phase 2 treatment was effective, patients could continue it until the completion of either 18 months of study (including time spent in phases 1 and 2) or until they completed 6 months of treatment in phase 2 (even if the 6-

TABLE 2. Treatment Discontinuation for the Intent-to-Treat Group of Patients Randomly Assigned to Clozapine or Another Atypical Antipsychotic

Variable	Clozapine (N=45)			Olanzapine (N=17)			Quetiapine (N=14)		
	Mean ^b	SD		Mean	SD		Mean	SD	
Modal dose (mg/day)	332.1	156.9		23.4	7.9		642.9	195.0	
	N ^b	%		N	%		N	%	
Number reaching maximum dose	—			10	59		10	71	
Number discontinued									
All causes	25	56		12	71		13	93	
Lack of efficacy ^c	5	11		6	35		6	43	
	Median	95% CI	p	Median	95% CI	p	Median	95% CI	p
Kaplan-Meier time to discontinuation (months)	10.5	7.3–16.1		2.7	1.9–11.9		3.3	1.0–4.9	
	Hazard Ratio ^d	95% CI	p	Hazard Ratio ^d	95% CI	p	Hazard Ratio ^d	95% CI	p
All causes: Cox model treatment comparisons									
Clozapine				0.57	0.29–1.16	0.12	0.39	0.19–0.80	0.01*
Olanzapine							0.69	0.30–1.54	0.37
Quetiapine									
Lack of efficacy: Cox model treatment comparisons									
Clozapine				0.24	0.07–0.78	<0.02*	0.16	0.04–0.54	0.004*
Olanzapine							0.66	0.20–2.22	0.51
Quetiapine									

^a Overall p is for the df=3 comparison of clozapine, olanzapine, quetiapine, and risperidone based on a Cox model for survival outcomes with adjustment for whether the patient had an exacerbation in the 3 months before study entry and whether the patient had been previously enrolled in phase 1A or phase 1B. If p<0.05, clozapine was compared with each atypical drug by means of a Hochberg adjustment (the smallest clozapine p value was compared to 0.05/3=0.0167), and the three atypical drugs were compared relative to p<0.05 by means of step-down/closed testing.

^b Modal dose and percentages for patients taking the maximum dose are based on the number of patients with nonmissing dose data: clozapine (N=37), olanzapine (N=17), quetiapine (N=14), and risperidone (N=13). Dose information was not available for some early dropouts. Maximal dose was not defined for clozapine, which was open label. p value for percent of patients reaching the maximal dose is from a test with df=2 comparing olanzapine, quetiapine, and risperidone with a Poisson regression accounting for differential exposure times and adjustment for whether the patient had an exacerbation in the 3 months before study entry and whether the patient had been previously enrolled in phase 1A or phase 1B.

TABLE 3. Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression (CGI) Scale Scores for Intent-to-Treat Patients Randomly Assigned to Clozapine or Another Atypical Antipsychotic

Endpoint Measure	Clozapine (N=43)				Olanzapine (N=17)				Quetiapine (N=14)			
	Mean	SE	N ^b	p	Mean	SE	N ^b	p	Mean	SE	N ^b	p
Total PANSS change in score for phase 2 baseline												
Month 3 (clozapine pairwise test)	-11.7	3.2	43		-3.2	2.3	17	0.22	2.5	4.8	13	<0.02*
Month 6	-18.4	3.3	33		-7.7	3.1	10		-1.3	6.8	8	
Positive PANSS change in score for phase 2 baseline												
Month 3	-4.1	1.1	43		-1.7	0.8	17		0.2	1.5	13	
Month 6	-4.9	1.1	33		-2.9	1.3	10		0.6	2.1	8	
Negative PANSS change in score for phase 2 baseline												
Month 3	-2.8	1.0	43		-0.6	0.9	17		0.0	1.5	13	
Month 6	-5.3	1.1	33		-0.7	0.7	10		-1.1	2.2	8	
General psychiatric PANSS change in score for phase 2 baseline												
Month 3 (clozapine pairwise test)	-4.7	1.5	43		-0.9	1.3	17	0.24	2.3	2.5	13	0.006*
Month 6	-8.2	1.6	33		-4.1	1.8	10		-0.8	3.5	8	
CGI severity change in score for phase 2 baseline												
Month 3 (clozapine pairwise test)	-0.7	0.1	41		0.1	0.2	15	<0.02*	0.2	0.3	13	0.003*
Month 6	-0.8	0.2	33		-0.2	0.4	10		-0.5	0.6	8	

^a p values, presented for descriptive purposes, are from a test with df=3 for treatment based on an ANCOVA with adjustment for baseline value and whether the patient had an exacerbation in the previous 3 months. If p<0.05, clozapine was compared with each atypical drug by means of a Hochberg adjustment (the smallest clozapine p value was compared to 0.05/3=0.0167), and the three atypical drugs were compared relative to p<0.05 with step-down/closed testing.

^b N represents the number of patients with nonmissing data at that time point.
*p<0.05 after Hochberg adjustment for multiple comparisons where applicable.

Risperidone (N=14)		Analysis ^a	
Mean	SD		
4.8	1.3		
N	%		Overall p
8	62		0.59
12	86		
6	43		
Median	95% CI		
2.8	1.1–4.0		
Hazard Ratio ^d	95% CI	p	Overall p
0.42	0.21–0.86	<0.02*	<0.03*
0.73	0.32–1.67	0.47	
1.07	0.48–2.37	0.87	
0.16	0.05–0.54	0.003*	0.01*
0.68	0.21–2.23	0.53	
1.03	0.32–3.28	0.96	

^c Kaplan-Meier 25th percentile was not estimable due to low event rates.

^d For pairwise comparisons of treatment groups, Cox model hazard ratios less than 1 indicate greater time until discontinuation for the first treatment.

*p<0.05 after Hochberg adjustment for multiple comparisons where applicable.

Risperidone (N=14)				Analysis ^a
Mean	SE	N ^b	p	Overall p
4.1	1.9	14	<0.03*	<0.03*
-0.3	2.8	6		0.11
0.8	0.7	14		0.06
-0.5	0.7	6		0.37
2.4	1.0	14		0.09
0.0	1.7	6		0.29
0.9	0.8	14	0.10	<0.04*
0.2	1.3	6		0.10
0.0	0.2	13	6.18	0.01*
-0.5	0.3	6		0.83

month period extended beyond 18 months of total study treatment). This article reports the results of the phase 2 efficacy trial, recommended to individuals who discontinued the previous phase 1 treatment because of inefficacy.

Participants

Inclusion criteria were ages 18–65 years, a diagnosis of schizophrenia (determined by the Structured Clinical Interview for DSM-IV), and decision-making capacity to provide informed consent. Exclusion criteria were mental retardation, other cognitive disorders, or past serious adverse reactions to any of the proposed treatments. Also excluded were patients experiencing their first psychotic episodes, patients with past evidence of profound treatment resistance, women who were pregnant or breast-feeding, or patients with serious, unstable medical conditions. Patients with brief prior periods of treatment with clozapine were allowed to enter the CATIE investigation as long as the reasons for stopping clozapine treatment had not been serious adverse events.

The appropriate institutional review boards approved the study at each site, and the patients or their legal guardians provided signed informed consent to participate.

Interventions

The patients assigned to clozapine (N=49) received open-label treatment. The schedule for dose titration and the maintenance doses were determined by the treating clinicians. Monitoring for agranulocytosis (weekly WBC counts) and myocardial inflammation (sedimentation rate, eosinophil count, creatine phosphokinase level, and ECGs at baseline and after 1, 2, and 4 weeks of treatment) was standardized. The patients assigned to the newer atypical antipsychotics received blinded capsules containing olanzapine, 7.5 mg (N=19), quetiapine, 200 mg (N=15), or risperidone, 1.5 mg (N=16), starting with one capsule each day. Doses were adjusted by the treating clinician within the range of one to four capsules a day. Overlap administration of the antipsychotic each patient received in the preceding phase was permitted for the first 4 weeks to allow gradual transition to the new phase 2 medication. Adjunctive and concomitant medications were permitted throughout the trial, except for additional antipsychotics. The patients were seen at least monthly. The drug package insert for quetiapine specifies that it is to be given twice a day, whereas olanzapine and risperidone may be given once a day. To protect the blinding of treatment with the newer atypical antipsychotics, half of the patients randomly assigned to olanzapine and risperidone were assigned to twice a day and half to once a day dosing. To minimize initial side effects, the patients assigned to quetiapine began treatment by receiving one 100-mg capsule on days 1 and 2, one twice a day on day 3, and one for the first dose on day 4. All patients assigned to twice-a-day dosing received five identical capsules to begin treatment.


Objectives and Outcomes

We hypothesized that there would be significant differences in the overall effectiveness of clozapine, olanzapine, quetiapine, and risperidone, in particular, and that treatment with clozapine would be significantly more effective than treatment with some or all of the newer atypical antipsychotics.

The primary outcome measure, time until treatment discontinuation for any reason, represents a synthesis of clinician and patient judgments that an assigned treatment was sufficiently efficacious and sufficiently tolerable to continue from visit to visit. Secondary outcomes included time to discontinuation for inadequate therapeutic benefit, intolerable side effects, or patient decision.

Raters for psychopathology and adverse event assessments were aware of the patients' assignment to clozapine versus a newer atypical antipsychotic, but they were blind to which newer

FIGURE 1. Enrollment, Allocation, Follow-Up, and Analysis of Patients Randomly Assigned to Clozapine or Another Atypical Antipsychotic



^a Phase 1B: double-blind treatment with olanzapine, quetiapine, or risperidone for those patients first assigned to perphenazine.

antipsychotic was used. Assessments and rater training are described in Swartz et al. (12). Because of the small size for this group, only limited and exploratory examinations of psychopathology measures and adverse event measures were undertaken.

Statistical Methods


Randomly assigned patients who received at least one dose of study medication comprised the intent-to-treat group. The main objective was the evaluation of clozapine versus olanzapine, quetiapine, and risperidone. Time from the beginning of phase 2 until treatment discontinuation was estimated by Kaplan-Meier survival curves. Treatment groups were compared with Cox proportional hazards regression models (11), with adjustment for whether the patient had an exacerbation in the 3 months before entering the study, tardive dyskinesia status, and whether the patient was initially randomly assigned to perphenazine (and thus had an additional treatment phase before entering phase 2). The overall difference between the four treatments was evaluated with a three degrees of freedom (df) test. If significant at $p \leq 0.05$, clozapine was then compared with each of the other atypical antipsychotics with a Hochberg adjustment for multiple comparisons (12), in which the largest p value was

compared to 0.05 and the smallest p value was compared to $0.05/3 = 0.017$. In addition, the three atypical drugs were compared to each other relative to $p \leq 0.05$ by means of step-down testing: pairwise comparisons were evaluated only if the p value from the test with $df=2$ was ≤ 0.05 . Similar analyses were conducted for time until phase 2 discontinuation because of lack of efficacy, intolerability, and patient decision. For these analyses, the patients discontinuing for any other reason were censored at the time of discontinuation.

Treatment groups were compared for change from phase 2 baseline score on the Positive and Negative Syndrome Scale (PANSS) (13) and the Clinical Global Impression (CGI) Scale severity score at months 3 and 6 by using an analysis of covariance (ANCOVA) with adjustment for whether the patient had an exacerbation in the 3 months before entering the study and baseline value. Time was classified into quarterly intervals of phase 2 treatment, represented by months 3, 6, 9, and 12. End-of-phase assessments were assigned to the next interval. Months 9–12 were excluded from statistical testing because of small group sizes.

Treatment groups were compared for baseline characteristics with an analysis of variance (ANOVA), a chi-square test, or Fisher's exact test. Overall treatment comparisons for safety outcomes are

FIGURE 2. Discontinuation Survival Curves of Patients Randomly Assigned to Clozapine or Another Atypical Antipsychotic



presented for descriptive purposes without correction for multiple comparisons. *p* values are based on Poisson regression or ANCOVA, both of which were adjusted for differential duration of phase 2 study drug. Fisher's exact test was used in cases of small group size. For laboratory parameters, exposure-adjusted ANCOVA least-squares means are presented, but because of skewed distributions, *p* values are from a rank ANCOVA.

Results

Baseline Characteristics and Disposition

Figure 1 depicts the enrollment, allocation, and follow-up of study patients; 1,493 patients were enrolled in the study and randomly assigned to treatment in phase 1. Of the 1,052 patients who were eligible for phase 2, 99 patients (9%) entered the "efficacy pathway" described in this article, 444 patients (42%) entered the "tolerability pathway," and 509 patients (48%) did not enter phase 2.

Table 1 displays the demographic and clinical characteristics of the 99 patients who were randomly assigned to treatment in phase 2. Their mean age was 39.7 years, and 81% were men; 64% were white, and 14% were Hispanic/Latino. They had had, on average, 12.6 years of education; 86% were unemployed, and 74% had never married. There were no significant differences across the treatment groups on these measures.

In the preceding phase, 19% had received olanzapine, 37% quetiapine, 30% risperidone, and 13% ziprasidone; they had been treated with these medications, on average,

for 4.5 months (SD=3.7) (median time to discontinuation=3.1 months). In the preceding phase, 86% had discontinued treatment because of an inadequate therapeutic benefit, 5% because of unacceptable side effects, 8% based on patient decision, and 1% based on administrative decision. There were no significant differences across the treatment groups on these measures.

The mean phase 2 baseline PANSS total score was 87.6, and the mean CGI severity item score was 4.6, i.e., in the moderately to markedly severe range of illness for the group. There were no significant differences across the treatment groups on these measures. The 99 patients who entered the phase 2 efficacy trial were, on average, sicker than the other patients (N=1,361) who entered the CATIE investigation, even at phase 1 baseline (PANSS total scores: mean=80.6, SD=17.5, versus mean=75.3, SD=17.5) ($t=2.9$, $df=1447$, $p=0.004$). Over the course of their participation in phase 1/1B, these 99 patients' conditions worsened, as demonstrated by a 7.0 (SD=18.5) point increase in their PANSS total scores (within-sample *t* test of change: $p<0.001$).

In comparison to the 444 patients who entered the phase 2 tolerability trial, the 99 patients who entered the phase 2 clozapine trial were less likely to be women (19% versus 31%) ($\chi^2=5.2$, $df=1$, $p<0.02$) and more likely to have had four or more prior hospitalizations for schizophrenia (58% versus 48%) ($\chi^2=4.8$, $df=1$, $p<0.03$). The phase 2 baseline PANSS total scores were higher for the patients enter-

TABLE 4. Safety Outcomes for Patients Randomly Assigned to Clozapine or Another Atypical Antipsychotic

Measure	Clozapine (N=49)				Olanzapine (N=19)					
	N	%			N	%				
Any moderate or severe adverse events by systematic inquiry	37	76			14	74				
Insomnia	2	4			3	16				
Hypersomnia/sleepiness	22	45			6	32				
Urinary hesitancy/dry mouth/constipation	10	20			0	0				
Sex drive/sexual arousal/sexual orgasm	16	33			2	11				
Gynecomastia/galactorrhea	1	2			1	5				
Menstrual irregularities ^b	0	0			0	0				
Incontinence/nocturia	5	10			0	0				
Sialorrhea	16	33			2	11				
Orthostatic faintness	6	12			1	5				
Skin rash	2	4			0	0				
Neurologic outcomes										
Abnormal Involuntary Movement Scale (AIMS) severity Index score $\geq 2^c$	7	21			3	21				
Barnes Global Clinical Assessment score $\geq 3^d$	2	5			0	0				
Simpson-Angus Extrapyramidal Rating Scale: mean score $\geq 1^e$	2	5			2	13				
Weight gain from phase 2 baseline $\geq 7\%^f$	8	20			2	13				
	Mean	SE	Median	Range	Mean	SE	Median	Range		
Weight change from phase 2 baseline										
Weight change (lb) ^g	1.4	2.8	0	-23 to 28	6.2	7.3	3	-23 to 109		
Weight change/treatment duration (lb/month) ^g	0.5	0.5	0	-2.7 to 6.9	1.0	0.8	1.4	-4.4 to 9.2		
	Mean	SE	Median	Exposure-Adjusted Mean	SE	Mean	SE	Median	Exposure-Adjusted Mean	SE
Blood chemistry change from phase 2 baseline to average of two largest values ^h										
Blood glucose level (mg/dl)	13.2	4.8	12.3	9.4	9.5	23.6	15.2	1.0	25.8	14.1
Hemoglobin A1C level (%)	0.10	0.13	0.20	0.11	0.11	0.13	0.13	0.10	0.12	0.16
Cholesterol level (mg/dl)	7.3	4.6	3.0	5.9	4.7	0.2	7.9	4.5	1.0	7.1
Triglyceride level (mg/dl)	52.6	20.8	51.0	43.8	21.2	-10.4	33.6	15.5	-5.3	32.0
Prolactin level (ng/ml)	-7.6	2.1	-5.3	-6.6	2.3	-4.1	2.3	-1.3	-4.7	3.4

^a p values, presented for descriptive purposes, are from a test with df=3 comparing all treatment groups. p values for percentages are from a Fisher's exact test, except for hypersomnia/sleepiness and any moderate or severe spontaneously reported adverse events that are based on Poisson regression accounting for differential exposure times. The p values for laboratory parameters are based on a ranked ANCOVA with adjustment for duration of exposure to the phase 2 study drug. The p values for change in weight and QTc are based on an ANCOVA with adjustment for duration of exposure to phase 2 study drug. p values for safety parameters with sparse frequencies were not generated and are denoted by "not tested."

^b Percentages for "Menstrual irregularities" are based on the number of female patients: clozapine (N=9), olanzapine (N=1), quetiapine (N=3), and risperidone (N=6).

^c Percentages for AIMS Severity Index ≥ 2 are based on the number of patients without tardive dyskinesia and with an AIMS Severity Index < 2 at baseline and at least one postbaseline measure: clozapine (N=34), olanzapine (N=14), quetiapine (N=10), and risperidone (N=11).

^d Percentages for the Barnes Global Clinical Assessment ≥ 3 are based on the number of patients with a Barnes Global Clinical Assessment score < 3 at baseline and at least one postbaseline measure: clozapine (N=41), olanzapine (N=17), quetiapine (N=13), and risperidone (N=13).

ing this efficacy trial than for the patients who entered the tolerability trial (mean=87.6, SD=20.2, versus mean=77.0, SD=18.6) (t=5.0, df=534, p<0.001).

Of the 318 patients who discontinued treatment with a newer atypical antipsychotic in phase 1 or 1B because of inadequate therapeutic benefit, 85 entered this phase 2 efficacy trial, 184 entered the phase 2 tolerability trial, and

49 did not continue in the main CATIE pathways. These three groups did not differ on age or on PANSS total score at the phase 1 baseline.

Mean modal doses prescribed during the trial were 332.1 mg/day for clozapine, 23.4 mg/day for olanzapine, 642.9 mg/day for quetiapine, and 4.8 mg/day for risperidone. Fifty-nine percent of olanzapine-treated patients,

Quetiapine (N=15)				Risperidone (N=16)				Analysis ^a		
N	%			N	%			p		
10	67			9	56			0.51		
2	13			5	31			0.02*		
5	33			4	25			1.00		
7	47			1	6			0.002*		
2	13			4	25			0.21		
0	0			0	0			0.76		
0	0			0	0			not tested		
2	13			2	13			0.40		
0	0			2	13			<0.02*		
4	27			1	6			0.30		
1	7			1	6			0.65		
1	10			0	0			0.39		
3	23			0	0			0.08		
2	17			0	0			0.25		
2	15			2	18			0.97		
Mean	SE	Median	Range	Mean	SE	Median	Range	p		
1.1	5.1	-1	-30 to 47	3.9	2.8	2	-5 to 23	0.71		
-0.4	1.1	-0.6	-9.5 to 5.1	0.5	0.6	0.6	-2.2 to 4.5	0.68		
Mean	SE	Median	Exposure-Adjusted Mean	SE	Mean	SE	Median	Exposure-Adjusted Mean	SE	p
-23.3	12.2	-17.0	-18.3	15.9	32.2	33.5	0.0	36.4	17.1	0.32
-0.10	0.15	0	-0.14	0.27	0.10	0.12	0.05	0.11	0.22	0.67
-13.0	6.8	-4.5	-11.0	8.1	-9.0	8.2	-9.0	7.4	8.7	0.25
-4.9	33.7	6.0	7.1	36.2	20.2	37.0	-39.0	30.0	39.0	0.86
-13.2	5.0	-18.4	-14.5	4.0	15.4	5.4	17.6	14.4	4.2	0.002*

^e Percentages for the Simpson-Angus Extrapyramidal Rating Scale score ≥1 are based on the number of patients with Simpson-Angus Extrapyramidal Rating Scale score <1 at baseline and at least one postbaseline measure: clozapine (N=41), olanzapine (N=16), quetiapine (N=12), and risperidone (N=13).

^f Percentages for weight gain are based on the number of patients with a baseline body weight value and at least one postbaseline measure: clozapine (N=41), olanzapine (N=16), quetiapine (N=13), and risperidone (N=11).

^g Range for weight change is the 5th percentile to 95th percentile, which excludes extreme outliers.

^h Patients were instructed to fast; nonfasting results were not excluded. The exposure-adjusted mean is the ANCOVA least-squares mean with adjustment for duration of exposure to phase 2 study drug. Because hemoglobin A1c was added to the protocol as part of a protocol amendment, the numbers of patients with a baseline and postbaseline assessment were smaller for this test: clozapine (N=15), olanzapine (N=7), quetiapine (N=3), and risperidone (N=4). For all other laboratory parameters: clozapine (N=39), olanzapine (N=16), quetiapine (N=13), and risperidone (N=11). Conversion of conventional units to International System of Units was as follows: blood glucose: mg/dl*0.05551=mmol/l, hemoglobin A1c: %*0.01=value, cholesterol: mg/dl*0.02586=mmol/l, triglycerides: mg/dl*0.01129=mmol/l, prolactin: ng/ml*1=g/l.

*p<0.05.

71% of quetiapine-treated patients, and 62% of risperidone-treated patients reached the maximum dose of four capsules a day.

Treatment Discontinuation

Discontinuation outcomes are presented in Table 2 and Figure 2. Following random assignment in the phase 2 ef-

ficacy pathway, 69% (N=62) of the intent-to-treat patients discontinued treatment before completion of the study (median treatment duration=5 months).

Forty-four percent (N=20) of the clozapine-treated patients, 29% (N=5) of the olanzapine-treated patients, 7% (N=1) of the quetiapine-treated patients, and 14% (N=2) of the risperidone-treated patients continued taking

their phase 2 medication for the duration of the trial. Median time until treatment discontinuation for any reason was 10.5 months for the clozapine-treated patients, 2.7 months for the olanzapine-treated patients, 3.3 months for the quetiapine-treated patients, and 2.8 months for the risperidone-treated patients (Figure 2). Clozapine was significantly superior to quetiapine (hazard ratio=0.39, $p=0.01$) and risperidone (hazard ratio=0.42, $p<0.02$) but not olanzapine. We repeated this analysis including only the intent-to-treat patients who discontinued phase 1/1B because of an inadequate therapeutic response ($N=78$). The results are similar, with clozapine (median time to discontinuation=13.7 months) significantly superior to quetiapine (3.4 months, hazard ratio=0.37, $p<0.02$) and risperidone (2.3 months, hazard ratio=0.20, $p<0.001$) but not olanzapine.

Treatment discontinuation due to lack of efficacy. Eleven percent ($N=5$) of the clozapine-treated patients, 35% ($N=6$) of the olanzapine-treated patients, and 43% ($N=6$) of both the quetiapine- and the risperidone-treated patients discontinued treatment because of lack of efficacy (Figure 2). Clozapine was significantly superior to olanzapine (hazard ratio=0.24, $p<0.02$), quetiapine (hazard ratio=0.16, $p=0.004$), and risperidone (hazard ratio=0.16, $p=0.003$).

Other reasons for treatment discontinuation. There were no significant differences between the treatments in time to discontinuation because of intolerable side effects or patient decision (Figure 2).

Psychopathology

At the 3-month assessment, the patients assigned to clozapine had greater reductions in the PANSS total score (mean=-11.7, $SE=3.2$) than the patients assigned to quetiapine (mean=2.5, $SE=4.8$, $p=0.02$) or risperidone (mean=4.1, $SE=1.9$, $p<0.03$) but not olanzapine (Table 3). A similar pattern was seen on the PANSS general psychopathology subscale, although clozapine was only substantially better than quetiapine. The patients assigned to clozapine had greater reductions on the Clinical Global Impression Scale for severity at 3 months (mean=-0.7, $SE=0.1$) compared to the patients assigned to olanzapine (mean=0.1, $SE=0.2$, $p<0.02$) and quetiapine (mean=0.2, $SE=0.3$, $p=0.003$).

Adverse Events

Adverse events and side effects are listed in Table 4. Because of small groups, outcomes were highly variable. All patients who entered this trial were treated with another newer antipsychotic at baseline; this may have decreased the likelihood that we would detect "new" occurrences of adverse events that have been associated, to a greater or lesser degree, with all of the antipsychotics used (e.g., weight gain). Insomnia was most common with risperidone (31%) and least common with clozapine (4%). Anticholinergic symptoms (urinary hesitancy, dry mouth, constipation) were most common with quetiapine (47%)

and somewhat common with clozapine (20%). Sialorrhea was most common with clozapine (33%). There were no noteworthy differences across the treatment groups in metabolic measures or the rate of use of hypoglycemic or lipid-lowering treatments. Prolactin levels rose in patients treated with risperidone and fell in patients in the other three treatment groups. In the clozapine group, one patient had a serious adverse event of eosinophilia, and one patient developed agranulocytosis. Both events led to discontinuation of treatment.

Discussion

This study is the first to compare clozapine to the newer atypical antipsychotics in a population of patients prospectively determined to have not improved during treatment with another newer antipsychotic drug. In this group of patients who had just discontinued a course of treatment with a newer atypical antipsychotic, treatment with clozapine was significantly more effective than switching to another of the newer atypical antipsychotics. In particular, patients receiving clozapine were significantly less likely to discontinue treatment for any reason than patients receiving quetiapine or risperidone. In addition, patients receiving clozapine were less likely to discontinue treatment because of inadequate therapeutic response than were patients receiving any of the newer atypical antipsychotics. These advantages for clozapine were strong enough to achieve statistical significance despite small groups.

The results of this study are consistent with previous studies finding clozapine more effective than conventional antipsychotics. Essock et al. (6) randomly assigned 227 severely ill patients with schizophrenia or schizoaffective disorder in Connecticut state hospitals to up to 2 years of open-label treatment with either clozapine or usual care with conventional neuroleptics. Clozapine-treated patients had fewer extrapyramidal side effects and disruptiveness than patients treated with usual care, but the groups did not differ on severity of psychopathology or quality of life. Clozapine-treated patients were not more likely to be discharged, but once they were, they were less likely to be readmitted. Of the 136 patients who began treatment with clozapine, 74% were still receiving clozapine at 1 year, and 66% were still receiving clozapine at 2 years. Of note, by the end of 2 years, 66% of the patients assigned to usual care had begun a trial of clozapine. Rosenheck et al. (14) randomly assigned 423 patients with treatment-resistant schizophrenia to up to 1 year of double-blind treatment with either clozapine or haloperidol. Fifty-seven percent of the clozapine-treated patients but only 28% of the haloperidol-treated patients completed the year of treatment. Clozapine-treated patients had slightly but significantly lower psychopathology scores and better quality-of-life scores than haloperidol-treated patients. Cloza-

pine-treated patients had significantly fewer days in the hospital over the year than haloperidol-treated patients (143.8 days versus 168.1). Agranulocytosis developed in three clozapine-treated patients; all recovered after clozapine was discontinued.

The major limitation of this study was that clozapine was administered open label. This could have led to bias in treatment discontinuation decisions by clinicians who viewed clozapine as the patients' "last best shot" at recovery and who, therefore, kept patients treated with clozapine longer. On the other hand, clozapine's burden of life-threatening side effects could also lead clinicians to discontinue patients who were not showing an early response. In addition, clozapine-treated patients had more frequent contact with clinical staff because of weekly laboratory monitoring and prescription renewals. In keeping with the effectiveness model of the CATIE investigation, we wished to preserve the ecological validity of all treatments; the blinding of treatment with clozapine would have required monitoring of all treatment groups for safety issues specific to clozapine. In addition, our group was small and did not offer adequate power for reasonable comparisons across the treatment groups on all adverse events.

Only 85 of 318 (27%) of the patients who discontinued a newer atypical antipsychotic in phase 1 because of inadequate therapeutic effects entered the phase 2 clozapine trial. Despite its therapeutic advantages, clozapine has been underused (15, 16), perhaps because of the array of serious side effects it may cause; these include agranulocytosis, myocarditis, other inflammatory reactions, seizures, obesity, diabetes mellitus, and other metabolic abnormalities. Extensive monitoring is required to avoid the consequences of these side effects (17, 18). An argument can be made to establish specialized "clozapine clinics" within systems of care, which have standardized monitoring in place to detect these side effects early and experienced clinicians who can intervene rapidly to limit their deleterious effects. Given the superior effectiveness of clozapine relative to all other antipsychotics, efforts to develop models of service delivery that would encourage its greater use are warranted.

Received Dec. 14, 2005; revision received Feb. 1, 2006; accepted Feb. 2, 2006. From the Clinical Research Service, John Umstead Hospital; the Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, N.C.; New York State Psychiatric Institute, Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York; the Department of Biostatistics, School of Public Health, and the School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, N.C.; Quintiles Inc., Research Triangle Park, N.C.; the Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tenn.; the Department of Psychiatry, Yale University School of Medicine, New Haven, Conn.; and the Division of Services and Intervention Research, NIMH, Bethesda, Md. Address correspondence and reprint requests to Dr. McEvoy, Clinical Research Service, John Umstead Hospital, 1003 12th St., Bldg. 32, Butner, NC 27705; jpmcevoy@duke.edu (e-mail).

Funding was provided by NIMH. IVAX Corporation donated clozapine and provided input on the dosage range for their drug only; they

had no other input into study design, analyses, or interpretation of the results.

Additional information on the CATIE investigation is included in a data supplement accompanying the online version of this article.

References

1. Claghorn J, Honigfeld G, Abuzzahab FS, Wang R, Steinbook R, Tuason V, Klerman G: The risks and benefits of clozapine versus chlorpromazine. *J Clin Psychopharmacol* 1987; 7: 377–384
2. Kane JM, Honigfeld G, Singer J, Meltzer HY, the Clozaril Collaborative Study Group: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. *Arch Gen Psychiatry* 1988; 45:789–796
3. Pickar D, Owen RR, Litman RE, Konicki E, Guitierrez R, Rapaport M: Clinical and biological response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. *Arch Gen Psychiatry* 1992; 49:345–353
4. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT: Clozapine in schizophrenic outpatients: effects on positive and negative symptoms. *Arch Gen Psychiatry* 1994; 151:20–26
5. Carpenter WT Jr, Conley RR, Buchanan RW, Breier A, Tamminga CA: Patient response and resource management: another view of clozapine treatment of schizophrenia. *Am J Psychiatry* 1995; 152:827–832
6. Essock SM, Hargreaves WA, Covell NH, Goethe J: Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. *Psychopharmacol Bull* 1996; 32:683–697
7. Volavka J, Czobor P, Sheitman B, Lindenmeyer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA: Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. *Am J Psychiatry* 2002; 159:255–262; erratum, 159: 2132
8. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B: Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. *Am J Psychiatry* 2001; 158:518–526
9. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, American Psychiatric Association Steering Committee on Practice Guidelines: Practice guideline for the treatment of patients with schizophrenia, 2nd ed. *Am J Psychiatry* 2004; 161(2 suppl)1–56
10. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens ML, Lieberman JA: The national institute of mental health clinical antipsychotic trials of intervention effectiveness (CATIE) project: schizophrenia trial design and protocol development. *Schizophr Bull* 2003; 29:15–31
11. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, the CATIE Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med* 2005; 353: 1209–1223
12. Swartz MS, Perkins DO, Stroup TS, McEvoy JP, Nieri JM, Haak DC: Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial. *Schizophr Bull* 2003; 29:33–43
13. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. *Schizophr Bull* 1987; 13:261–276
14. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D, Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia: A comparison of clozapine and haloperidol in hospitalized pa-

PHASE 2 CATIE RESULTS: CLOZAPINE VERSUS OTHER ATYPICALS

- tients with refractory schizophrenia. *N Engl J Med* 1997; 337: 809–815
15. Taylor DM, Young C, Paton C: Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. *J Clin Psychiatry* 2003; 64:30–34
 16. Weissman EM: Antipsychotic prescribing practices in the veterans healthcare administration—New York metropolitan region. *Schizophr Bull* 2002; 28:31–42
 17. Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, Freudenreich O, Evins E, Cather C, Goff DC: Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. *J Clin Psychiatry* 2005; 66:1116–1121
 18. Wehmeier PM, Heiser P, Remschmidt H: Myocarditis, pericarditis and cardiomyopathy in patients treated with clozapine. *J Clin Pharm Ther* 2005; 30:91–96